Industry news · event 2026-03-09 · 3 min read
Hims & Hers Closes Compounded GLP-1s to New Patients, Goes Brand-Only (March 2026)
Under a DOJ referral and the February enforcement climate, the biggest name in telehealth weight loss stopped compounded GLP-1 sign-ups in March 2026 — the clearest signal yet of where the market is heading.
GRGLP1ProviderCompare Research Team
Pricing & policy research
Quick answerUnder a DOJ referral and the February enforcement climate, the biggest name in telehealth weight loss stopped compounded GLP-1 sign-ups in March 2026 — the clearest signal yet of where the market is heading.
The compounded era's biggest brand blinked in March 2026: Hims & Hers closed its compounded GLP-1 program to new patients and moved new weight-loss starts to brand-name fulfillment, weeks after February's warning-letter wave and amid a reported Department of Justice referral concerning its marketing.
The strategic read matters more than the corporate news. Hims had the scale, legal budget, and margin incentive to defend compounded GLP-1s longer than anyone — and chose not to. Together with Ro's brand pivot and WeightWatchers Clinic's coverage-first model, the industry's most visible tier now sells the FDA-approved products, leaving compounded supply to a long tail of smaller programs operating on the patient-specific 503A theory.
For shoppers the consequence is concrete: the famous names in our directory are mostly brand doors now (your price = manufacturer rate or copay), while the verified compounded price leaders are companies whose main marketing asset is a published number — which is precisely why evidence tiers and pharmacy disclosure, not logo recognition, drive our formula.